Brief: Regenxbio Presents Positive Twelve-Month Pivotal Data From Phase I/Ii/Iii Campsiite® Trial Of Rgx-121 For Treatment Of Mps Ii
05/09/2025 12:05
Regenxbio Inc RGNX.O: REGENXBIO PRESENTS POSITIVE TWELVE-MONTH PIVOTAL DATA FROM PHASE I/II/III CAMPSIITE® TRIAL OF RGX-121 FOR TREATMENT OF MPS II REGENXBIO INC - RGX-121 IMPROVES OUTCOMES FOR MPS II PATIENTS REGENXBIO INC - PRIMARY ENDPOINT OF CSF HS D2S6 REDUCTION MET REGENXBIO INC - FDA DECISION ON RGX-121 EXPECTED BY FEBRUARY 8, 2026 Source text: ID:nPn5glkbna Further company coverage: RGNX.O
Recent news on REGENXBIO
See all newsBrief: Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date
Regenxbio climbs as new director buys nearly $1 million of stock
Brief: Regenxbio Strengthens Board Of Directors With Appointment Of Greg Ciongoli
U.S. STOCKS ON THE MOVE-Strategy, Ecovyst, Azenta
U.S. STOCKS ON THE MOVE-Azenta, Qiagen NV, Capricor Therapeutics